Jawhar et al. [111,112] have reported that variants in 3 critical genes, namely SRSF2, ASXL1, and RUNX1 (S/A/R gene panel) can influence overall survival and are thus the most important predictive indicators of a poor outcome in patients with SM. This evidence concerns the gene RUNX1 and systemic mastocytosis.